tbuckley/cabot-search huggingface dataset:
A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma
Authors: J. Ledermann, J. Sehouli, B. Zurawski, F. Raspagliesi, U. De Giorgi, S. Banerjee, J. Arranz Arija, M. Romeo Marin, A. Lisyanskaya, R.L. Póka, S. Mihutiu, J. Markowska, C. Cebotaru, A. Casado Herraez, N. Colombo, N. Kovalenko, E. Kutarska, M. Hall, R. Belli, A. Zurlo
Journal: Annals of Oncology (2017)
Randomized study comparing high-dose (HD) influenza vaccine to standard-dose (SD) influenza vaccine in patients with breast cancer age &lt; 65 receiving chemotherapy.
Authors: Saad Jamshed, Ann R Falsey, Paul Thushara, Jennifer Walker, Edward E Walsh
Journal: Journal of Clinical Oncology (2017)

e21695 Background: Patients on chemotherapy often fail to develop a robust response to influenza vaccine. We had previously demonstrated that HD vaccine improved immunogenicity in cancer patients receiving chemotherapy. The present subgroup analysis evaluates immunogenicity &amp; tolerability of HD to SD vaccine specifically in breast cancer pts &lt;65 yrs receiving chemotherapy. Methods: 35 breast cancer pts were randomized to receive either SD or HD (17 vs 18) vaccine on day1 of chemotherapy during 2 influenza seasons. HAI titers were measured prior to &amp; 4-wks after vaccination. HAI were summarized as geometric mean titer (GMT) and seroconversion (&gt;4-fold titer rise) &amp; seroprotection (GMT ≥40) rates calculated. t-test was used to compare log2-transformed GMT titers between groups and χ 2 for comparison of seroconversion and seroprotection rates. Results: 2 pts were included only once (yr 1) as they received study vaccine both yrs. Mean age (50.4 vs 51.3 yrs) and baseline HAI titers were equivalent; 81 vs 88% were receiving therapy with curative intent in SD vs HD arms, respectively. Both vaccines were well tolerated with no SAEs. Post vaccination GMT were greater after HD vaccine, but was statistically significant only for H3N2 virus. Seroconversion rates for B strain was significantly improved with HD vaccine while seroprotection was excellent for all antigens in both arms. Conclusions: Trivalent HD influenza vaccine can be safely administered with increased seroconversion over SD vaccine. Most patients with breast cancer should be offered vaccination even if they are receiving chemotherapy, as they demonstrate robust response to either influenza vaccine. A larger study is needed to show clinical benefits with HD vaccine. Clinical trial information: NCT01666782. [Table: see text]
FiRe - il Gruppo di lavoro Finlandese sulla Resistenza antimicrobica
Authors: A Nissinen, P Huovinen
Journal: Eurosurveillance (2000)

ll Gruppo di lavoro Finlandese sulla Resistenza antimicrobica (FiRe), creato nel 1991, ha messo a punto un metodo di routine standardizzato per testare la sensibilita dei batteri agli antibiotici. Questo metodo permette di ottenere risultati affidabili e comparabili sia a scopo diagnostico sia epidemiologico. Gli ultimi risultati mostrano che la proporzione di Streptococcus pneumoniae resistente ai macrolidi sta aumentando e che sta diminuendo la sensibilita ai fluorochinoloni dei ceppi di salmonella di origine straniera, mentre e rimasta bassa in Finlandia la prevalenza di MRSA ed e raro il Mycobacterium tuberculosis multiresistente.
Metastatic pancreatic cancer: Real Life data from the german quality of life and translational research on pancreatic cancer study (QoliXane)
Authors: S-E. Al-Batran, A. Reichart, C. Schoenherr, G. zur Hausen, C. Pauligk, B. Schöttger, G. Siegler, S. Doerfel, A. Aldaoud, L. Hahn, J. Schubert, O. Waidmann, J. Trojan, H-G. Hoeffkes, R. Schnell, M. Koenigsmann, W. Blau, J. Uhlig, N. Homann, T.O. Götze
Journal: Annals of Oncology (2017)
Improving Outcomes After Out-of-Hospital Cardiac Arrest
Authors: Terence Valenzuela, Andrew J. Harrell, Graham Nichol
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
Authors: H. Scher, R.P. Graf, A. Jendrisak, B. McLaughlin, E. Barnett, N.A. Schreiber, J. Lee, J. Kelvin, Y. Wang, M. Landers, R. Dittamore
Journal: Annals of Oncology (2017)
ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis
Authors: Abi Vijenthira, Matthew C Cheung, Chai Wye Phua, Kelvin Chan, Joanna Graczyk, Rena Buckstein, Anca Prica
Journal: Blood (2016)
Programmable Hydrogels for Cell Encapsulation and Neo‐Tissue Growth to Enable Personalized Tissue Engineering
Authors: Stephanie J. Bryant, Franck J. Vernerey
Journal: Advanced Healthcare Materials (2017)

Abstract Biomimetic and biodegradable synthetic hydrogels are emerging as a promising platform for cell encapsulation and tissue engineering. Notably, synthetic‐based hydrogels offer highly programmable macroscopic properties (e.g., mechanical, swelling and transport properties) and degradation profiles through control over several tunable parameters (e.g., the initial network structure, degradation kinetics and behavior, and polymer properties). One component to success is the ability to maintain structural integrity as the hydrogel transitions to neo‐tissue. This seamless transition is complicated by the fact that cellular activity is highly variable among donors. Thus, computational models provide an important tool in tissue engineering due to their unique ability to explore the coupled processes of hydrogel degradation and neo‐tissue growth across multiple length scales. In addition, such models provide new opportunities to develop predictive computational tools to overcome the challenges with designing hydrogels for different donors. In this report, programmable properties of synthetic‐based hydrogels and their relation to the hydrogel's structural properties and their evolution with degradation are reviewed. This is followed by recent progress on the development of computational models that describe hydrogel degradation with neo‐tissue growth when cells are encapsulated in a hydrogel. Finally, the potential for predictive models to enable patient‐specific hydrogel designs for personalized tissue engineering is discussed.
Plasma protein fingerprinting and machine learning for the diagnosis of small intestinal neuroendocrine tumors: The nordic NET biomarker group EXPLAIN study
Authors: M.M. Kjellman, S. Welin, U. Knigge, H. Gronbaek, H. Sorbye, E. Thiis-Evensen, M. Thyregod Jørgensen, V. Johanson, C. Schalin-Jäntti, P. Myrenfors, T. Ström, K. Becker, R. Belusa
Journal: Annals of Oncology (2017)
Persistent lapses at Cornwall hospital trust lead to special measures
Authors: Jacqui Wise
Journal: BMJ (2017)

Royal Cornwall Hospitals NHS Trust should be placed in special measures, the Care Quality Commission (CQC) has said.1

The health watchdog rated the trust overall as inadequate for being safe, responsive, and well led, although it is rated as good for caring.

The Royal Cornwall Hospital at Treliske was rated inadequate overall, with surgery, maternity and gynaecology, end of life, and outpatient services also rated as inadequate. Critical care and children and young people’s services were rated as good. Services provided at St Michael’s Hospital in Haylee and West Cornwall Hospital in Penzance were rated good, with the Penrice Birthing Centre at St Austell requiring improvement.

At the time of the latest inspection in July 2017 the trust was asked to make a number of immediate …
Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.
Authors: Karen Kelly, Jeffrey R. Infante, Matthew H. Taylor, Manish R. Patel, Michael S. Gordon, Deborah Jean Lee Wong, Nicholas Iannotti, Janice M. Mehnert, Anja Loos, Helga Koch, Isabell Speit, James L. Gulley
Journal: Journal of Clinical Oncology (2017)

3059 Background: Avelumab is a fully human IgG1 anti–PD-L1 antibody with clinical activity in several tumor types. Pooled safety data from a large phase 1 trial in various tumors and a phase 2 trial in Merkel cell carcinoma (NCT01772004, NCT02155647) were analyzed to further characterize the safety profile of avelumab. Methods: Patients (pts) received avelumab 10 mg/kg 1-hour IV Q2W until progression, unacceptable toxicity, or withdrawal. Treatment-related adverse events (TRAEs) were graded by NCI CTCAE. In post hoc analyses, immune-related adverse events (irAEs) were identified via an expanded AE list and medical review, and infusion-related reaction (IRR) events were identified based on prespecified MedDRA terms, occurring within 1 day or related symptoms that resolved within 2 days of infusion. Results: In 1,738 pts analyzed (phase 1, n = 1,650; phase 2, n = 88) who received ≥1 dose of avelumab for a median of 12 weeks (range 2-138), the most common any grade TRAEs were fatigue (n = 307, 18%), IRR (n = 295, 17%), and nausea (n = 150, 9%). 177 pts (10%) had a grade ≥3 TRAE; most common were fatigue and elevated lipase (17 [1%] each). TRAEs led to discontinuation in 107 pts (6%). Four pts (0.2%) died due to a TRAE. Any grade irAEs occurred in 247 pts (14%), which were grade ≥3 in 39 pts (2%) and considered serious in 43 pts (2%). The most common any grade irAEs were thyroid disorder (n = 98, 6%) and rash (n = 90, 5%). Other irAEs (eg, colitis, hepatitis, pneumonitis, adrenal insufficiency, myositis) each occurred in &lt; 2%. irAEs led to discontinuation in 34 pts (2%). IRR or related symptoms (eg, chills, pyrexia, hypersensitivity) occurred in 439 pts (25%), which were grade 3 in 9 pts (0.5%) and grade 4 in 3 pts (0.2%). An IRR occurred at first infusion in 79% and within first 4 doses in 99%; 63/439 pts (14%) had IRR recurrence in later cycles. IRR led to dose interruption in 152 (9%), infusion rate reduction in 124 (7%), and discontinuation in 35 pts (2%). Conclusions: This large pooled analysis confirms that avelumab has an acceptable safety profile. A minority of pts experienced a grade ≥3 TRAE or irAE and discontinuation due to TRAEs was uncommon. IRRs mostly occurred at first infusion and the rate of recurrence was low. Clinical trial information: NCT01772004, NCT02155647.
Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-fluorouracil (F), leucovorin (L) and oxaliplatin (O; chronoIFLO4) combination at home
Authors: P. Innominato, S. Komarzynski, M. Bouchahda, A. Ulusakarya, M. Haydar, A. Karaboué, F. Levi
Journal: Annals of Oncology (2017)
Tumor metabolism, blood flow changes, and prognosis by positron emission tomography: A prospective cohort of locally advanced breast cancer patients
Authors: L. Dunnwald, J. Gralow, G. Ellis, R. Livingston, H. Linden, J. Specht, R. Doot, T. Lawton, W. Barlow, D. Mankoff
Journal: Journal of Clinical Oncology (2007)

506 Background: Breast cancer patients with locally advanced tumors receive preoperative chemotherapy to provide early systemic treatment and assess in-vivo tumor response. Positron emission tomography (PET) has been used to follow tumor response to therapy, as pathologic response is predictive of patient outcome. We evaluated the prognostic utility of serial quantitative PET tumor blood flow (BF) and metabolism measurements. Methods: Fifty-five women with a primary diagnosis of locally advanced breast carcinoma (LABC) underwent dynamic [18F]-FDG and [15O]-water PET scans prior to and at midpoint of neoadjuvant chemotherapy. The FDG metabolic rate (MRFDG), transport (K1), and flux (Ki) parameters were calculated, and tumor blood flow was estimated from the [15O]-water study. Associations between tumor BF and MRFDG measurements and disease-free survival (DFS) and overall survival (OS) were evaluated using the Cox proportional hazards model. Results: Patients that had an increase in BF and K1, from baseline to mid-therapy measurements, had elevated recurrence and mortality risks compared to patients that had reductions in BF and MRFDG values. In multivariate analysis, changes in BF and K1 remained independent prognostic indicators of DFS and OS survival. Conclusions: PET measurements of tumor response prior to completion of neoadjuvant chemotherapy were predictive of patient outcome. Patients that failed to have a decline in BF and K1 experienced higher risks of recurrence and mortality that was largely independent of clinical tumor characteristics assessed in this study. These results suggest that tumor perfusion, measured directly by [15O]-water or indirectly by dynamic FDG PET, is highly predictive of outcome in neoadjuvantly treated breast cancer. No significant financial relationships to disclose.
Medidas de control de SARM adoptadas por los Países Bajos, a raíz de la expansión de la Unión Europea
Authors: J H T Wagenvoort
Journal: Eurosurveillance (2000)

La politica nacional de los Paises Bajos destinada a prevenir la propagacion de Staphylococcus aureus resistentes a la meticilina (SARM) ha demostrado que es posible impedir y prevenir que los SARM se vuelvan endemicos en los hospitales. La implantacion de medidas eficaces contra los SARM tambien ayudara a prevenir la propagacion de otras infecciones nosocomiales. Una politica comun a toda la Union Europea paliaria en gran medida el problema que representan los SARM.
An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
Authors: I. Okamoto, H. Udagawa, S. Kanda, T.H. Han, I. Lakatos, F. Zhang, S. Okubo, C. Scripture, M. Takeda, H. Akamatsu, T. Tamura
Journal: Annals of Oncology (2017)
Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC)
Authors: D. Planchard, E.F. Smit, H.J.M. Groen, J. Mazieres, B. Besse, Å. Helland, V. Giannone, A. D'Amelio, P. Zhang, B. Mookerjee, B. Johnson
Journal: Annals of Oncology (2017)
Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.
Authors: Daniel J. DeAngelo, Elias Jabbour, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Giovanni Martinelli, Susan Mary O'Brien, Kongming Wang, Tao Wang, M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Anjali S. Advani, Hagop M Kantarjian
Journal: Journal of Clinical Oncology (2016)

7028 Background: InO, an anti-CD22 antibody-calicheamicin conjugate, showed superior response vs standard care for R/R ALL in the phase III INO-VATE trial. Herein, effects of prior therapy on response and toxicities were assessed in patients (pts) receiving InO. Methods: Per protocol, intent-to-treat analyses of complete remission [CR]/CR with incomplete hematologic recovery [CRi] included the first 218 of 326 pts randomized (ITT218). The safety population included 139 pts who received ≥ 1 InO dose (max 1.8 mg/m2/cycle [0.8 mg/m2 on d1; 0.5 mg/m2 on d8 and 15 of a 21–28 d cycle for ≤ 6 cycles]). Minimal residual disease (MRD) negativity was assessed by central flow cytometry ( < 0.01%). Data as of October 2, 2014 are presented (trial ongoing). Results: 109 pts in the ITT218 received InO (CR/CRi rate, 81% [95% CI, 72–88]; MRD negativity rate in responders, 78% [95% CI, 68–87]; median remission duration [DoR], 4.6 [95% CI, 3.9–5.4] mo). 67% and 32% of pts received InO as salvage (S) 1 and S2 (missing, n = 1). For S1 vs S2, response was numerically higher, MRD-negativity was similar, and DoR was numerically longer (Table). CR/CRi rate was numerically lower for pts with (n = 17) vs without (w/o) (n = 92) prior SCT (77% [95% CI, 50–93] vs 82% [72–89]). In the safety population, Gr ≥ 3 febrile neutropenia rates were similar for S1 (n = 95) vs S2 (n = 43) (both 23%) and for pts with (n = 24) vs w/o (n = 115) prior SCT (29% vs 23%). Any grade hepatobiliary AE rates were significantly higher in S2 vs S1 (47% vs 17%; P< 0.001) and numerically higher for pts with vs w/o prior SCT (42% vs 23%). For S1 vs S2, 36 vs 11 pts had poststudy SCT. Veno-occlusive liver disease (VOD) including post-SCT VOD occurred in 8% of S1 vs 16% of S2 pts (2 fatal in S1); in 21% with vs 9% w/o prior SCT (1 fatal in each cohort). Conclusions: InO may provide clinical benefit in pts with R/R ALL for both S1 and S2 therapy; hepatotoxicity risk increases with number of prior therapies and prior SCT. Clinical trial information: NCT01564784.% (95% CI)a S1 (n = 73) S2 (n = 35) CR/CRib 88 (78–94) 69 (51–83) CR 43 (31–55) 23 (10–40) CRi 45 (34–57) 46 (29–63) MRD-negativity in responders 78 (66–88) 79 (58–93) Median DoR, mo 5.2 (3.0–5.8)c 4.2 (3.2–4.6)d aITT218; bBest response (1–6 cycles); cn = 62; dn = 23
Légionellose associée aux voyages en Europe : 2002
Authors: K D Ricketts, B McNaught, C A Joseph
Journal: Eurosurveillance (2004)

En 2005, 755 cas de legionellose associee aux voyages dont les premiers symptomes sont survenus en 2005 ont ete declares par 20 pays au reseau de surveillance EWGLINET. Au total, 85,8% des cas ont ete diagnostiques par le test d’antigene urinaire, et 37 cultures ont ete obtenues. Vingt-neuf deces ont ete rapportes, soit un taux de mortalite de 3,8% (en baisse compare a 5,6% en 2004). Quatre vingt treize nouveaux foyers de cas ont ete detectes, dont 36,6% ne l’auraient pas ete sans EWGLINET. Cent vingt deux lieux de villegiature ont fait l’objet d’une investigation et le nom de neuf d’entre eux a ete publie sur le site web de EWGLI.
Factors predicting adherence to a tailored-dose adjuvant treatment based on geriatric assessment in elderly people with colorectal cancer: A prospective study
Authors: M. Antonio, J. Saldaña, A. Carmona-Bayonas, R. Salazar, V. Navarro, C. Tebé, J.M. Borras
Journal: Annals of Oncology (2017)
KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution
Authors: C. Erasun Lecuona, M.T. Moran Bueno, L. Vila, I. Teruel, L. Angelats, A. Ferrando, A. Plaja, P. Torres, E. Lopez, R. Muriel, A.M. Muñoz-Marmol, J.L. Mate, J.M. Velarde, E. Carcereny Costa
Journal: Annals of Oncology (2017)
Statins in systemic lupus erythematosus
Authors: Carlos Abud-Mendoza
Journal: Annals of the Rheumatic Diseases (2017)

Statins represent an important therapeutic option for prescription by rheumatologists due to their preventive effects related to cardiovascular disease as well as their immunoregulatory activity.

De Jong et al 1 recently published a report emphasising the use of statins as safety drugs, whose diverse effects in immune modulation could be related to autoimmune disorders. Although De Jong’s cohort shows no association with autoimmune disease development such as systemic lupus erythematosus (SLE), in our view, the data could support potential prevention of SLE.

Fasano et al 2 recently …
SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials
Authors: J. Arranz Arija, B. Pérez Valderrama, Á. Rodríguez Sánchez, I. Chirivella González, U. Anido Herranz, J.P. Maroto Rey, M.J. Miranda Pallares, M.A. Climent Duran, G. Crespo Herrero, J.A. Meana Garcia, A. Rodriguez-Vida, R. Fernandez-Rodriguez, C. Santander, G. Rubio Romero, S. Vazquez Estevez, O. Fernandez Calvo, M.B. Gonzalez Gragera, E. Almagro Casado, S. Perez Ramirez, P. Borrega García
Journal: Annals of Oncology (2017)
GW28-e0694 The association between single nucleotide polymorphism -204A&gt;C [rs 3808607] of cyp7A1 gene and markers of diastolic dysfunction for hypertension patients with type 2 diabetes mellitus
Authors: Demikhova Nadiia, Chernatska Olga, Maslenko Anna, Rudenko Tatiana, Prykhodko Olga
Journal: Journal of the American College of Cardiology (2017)
Decisions and supports around clinical trial participation: A national study by Cancer Trials Ireland
Authors: C. Kelly, R. Feighery, J. McCaffrey, M. Higgins, M. Smith, S. O'Reilly, A. Horgan, J. Walshe, R. McDermott, D. O'Donnell, P.G. Morris, M. Keane, M. Martin, C. Murphy, K. Duffy, A. Mihai, J. Armstrong, E. Mulroe, V. Murphy, C.M. Kelly
Journal: Annals of Oncology (2017)
Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)
Authors: A.M. Oza, P. Combe, J. Ledermann, S. Marschner, A. Amit, T. Huzarski, N. Lainez Milagro, A. Savarese, C. Scott, M.O. Nicoletto, P. Harter, T. Enomoto, G.S. Sonke, J-W. Kim, I. Vergote, A. Allen, E. Pujade-Lauraine
Journal: Annals of Oncology (2017)
A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04
Authors: A. Ocana Fernandez, M. Ruiz Borrego, M. Gil Martin, S. Antolin, M. Atienza, A. Montaño, N. Ribelles, A. Guerrero, M. Muñoz, I. Fernández-Pérez, A. Urruticoechea, A. Falcon Gonzalez, S. Pernas Simon, J. Prato Varela, M.J. Escudero, S. Benito, R. Caballero, E. Carrasco, F. Rojo, A. Pandiella
Journal: Annals of Oncology (2017)
Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes
Authors: Marta Rodríguez, Cristina Bajo-Santos, Nina P. Hessvik, Susanne Lorenz, Bastian Fromm, Viktor Berge, Kirsten Sandvig, Aija Linē, Alicia Llorente
Journal: Molecular Cancer (2017)

The aim of this study was to identify microRNAs in urinary exosomes that are differently expressed in prostate cancer patients and healthy donors. For this purpose, RNA was extracted from urinary exosomes from 20 prostate cancer patients and 9 healthy males and the microRNAs were analyzed by next generation sequencing. Interestingly, 5 microRNAs – miR-196a-5p, miR-34a-5p, miR-143-3p, miR-501-3p and miR-92a-1-5p – were significantly downregulated in exosomes from prostate cancer patients. Furthermore, RT-qPCR analysis of an independent cohort of 28 prostate cancer patients and 19 healthy males confirmed that miR-196a-5p and miR-501-3p were downregulated in prostate cancer samples. These results suggest that specific microRNAs in urinary exosomes might serve as non-invasive biomarkers for prostate cancer. In particular, miR-196a-5p and miR-501-3p are promising biomarkers that need to be further studied in large patient cohorts.